Skip to content

PHARMA-LIBIN

Absorbed by MULTIPHARMA on 27-06-2014 KBO/BCE: BE 0438.007.359

Annual accounts 2013

full format, filed on 05-06-2014, 56 days before the deadline
€1.5m
-€47,568
▲ €219,337
-€39,130
▲ €215,225
-€146,048
▲ €86,275
-113.7%
▼ 99.7 percentage points
0.30
▼ 0.51

Money flows

of every €100 of turnover, €10.30 was lost in 2013

Balance sheet

balance sheet total €220,372 on 31-12-2013
What the company ownsHow it is paid for

in euro

in euro

Staff

€50,537

Staff costs divided by the average number of full-time equivalents.

-6 employees

employees who joined employees who left

In 2013, 1 employee joined and 7 left.

Key figures and ratios

per financial year, computed from the annual accounts
Line Trend201320122011201020092008200720062005200420032002
-39,130-254,354-2,14848,38226,0064,37081,25281,650----
-146,048-232,323-66647,53232,8561,64368,89570,763----
02,517-1,9964,4902,5316,9253,500117,813----
32,276-7,352-11,8811,4003,2631,899-9,046-30,97130,468-1,3543,206-
-330,976-141,222129,230131,276100,10365,61280,53924,484-23,003-57,666-118,508-135,212
-3.2%-----------
-113.7%-14.0%21.1%24.2%20.8%21.7%28.3%21.4%20.9%18.7%6.5%5.5%
0.300.811.271.291.211.151.251.070.930.810.690.54
0.300.630.890.980.770.740.660.510.380.380.430.30
--3.753.133.803.602.543.673.794.3414.4717.14
---16.0%12.7%4.8%-16.2%27.2%22.8%27.8%60.7%28.0%71.2%
-70.1%-35.6%-3.4%3.1%1.0%-3.5%7.7%4.9%5.8%11.3%1.8%3.9%
3 days-----------
4 days-----------

Debt to equity is not shown because equity is negative. Debt divided by negative equity means nothing.

A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.

Filed annual accounts

as filed with the National Bank, click a year to choose it
Line Trend201320122011201020092008200720062005200420032002
Balance sheet: assets
20/58 220,372687,047707,239712,856723,796660,631589,781567,002448,679404,627460,745389,127
21/28 80,49288,93199,407124,507145,620168,764186,700206,675----
22/27 73,49281,93093,209118,309139,422162,567180,502200,477125,803147,479184,611221,851
22 70,68776,79587,015106,745126,475145,120159,923178,49480,23094,450108,671122,891
23 --1,1974,1153,0475,9918,9349,26011,68112,21314,41816,341
24 2,8045,1354,9987,4499,90011,45611,64512,72333,89240,81661,52282,619
28 7,0017,0016,1976,1976,1976,1976,1976,1976,1976,1976,1976,197
29/58 139,880598,116607,832588,350578,176491,867403,082360,327316,679250,951269,937161,079
3 -129,581180,471140,247210,097178,114189,364189,163186,136132,394103,29071,579
30/36 -129,581180,471140,247210,097178,114189,364189,163186,136132,394103,29071,579
40/41 102,182435,514411,809411,149340,185289,651183,005138,68771,99590,134136,76158,284
40 10,55063,32499,95390,74366,06871,76659,98766,38959,01962,158105,88855,357
41 91,632372,190311,856320,406274,117217,885123,01872,29712,97627,97630,8732,927
50/53 ----00------
54/58 37,6975,42212,77424,65523,25619,99318,09427,14058,11127,64328,99725,791
490/1 -27,6002,77812,2984,6374,10912,6185,3384377808895,425
Balance sheet: equity and liabilities
10/49 220,372687,047707,239712,856723,796660,631589,781567,002448,679404,627460,745389,127
10/15 -250,483-95,997148,877172,647150,718143,536166,754121,33593,70875,70329,78821,450
10/11 62,00062,00062,00062,00062,00062,00062,00062,000----
10 --------62,00062,00062,00062,000
100 62,00062,00062,00062,00062,00062,00062,00062,00062,00062,00062,00062,000
13 6,2006,200110,647110,647104,754104,754104,75459,33531,70828,84528,84528,845
130 6,2006,2006,2006,2006,2006,2006,2006,2005,9623,0993,0993,099
133 --104,447104,44798,55498,55498,55453,13525,74625,74625,74625,746
14 -318,683-164,197-23,7700-16,036-23,218------
17/49 470,855783,044558,362540,209573,078517,095423,027445,667354,971328,924430,957367,677
17 -42,96155,63467,56478,79489,36599,316108,6835,06013,73741,73071,112
170/4 -42,96155,63467,56478,79489,36599,316108,6835,06013,73741,73071,112
42/48 470,855739,339478,602457,073478,073426,255322,542335,843339,682308,617388,445296,291
42 -13,69611,93011,23010,57114,21111,07118,9628,67629,11743,99530,506
43 -23,90923,09326,99255,59730,824---9,55019,77623,945
430/8 -23,90923,09326,99255,59730,824---9,55019,77623,945
44 13,661627,320426,119395,408384,624360,117280,199261,371268,809221,268214,550200,327
440/4 13,661627,320426,119395,408384,624360,117280,199261,371268,809221,268214,550200,327
46 ---0852-----4,218-
45 17,74219,01516,98021,81819,63114,61110,23235,86631,62623,68223,48517,983
450/3 9,259-0471--019,7037,8142,6962,670115
454/9 8,48319,01516,98021,34719,63114,61110,23216,16323,81220,98620,81517,868
47/48 439,45355,4004801,6266,7976,49221,04019,64530,57125,00082,42123,530
492/3 -74524,12615,57216,2111,4751,1691,14110,2296,570782274
Income statement
70 1.5m-----------
76A 3291,623-01,57204,120-----
9900 142,523-44,817190,546200,493161,408130,262213,110214,739217,847208,062189,994184,709
60/61 1.4m-----------
62 176,880163,405170,519133,207125,346115,806107,506109,449----
630 8,43812,55023,10425,60325,67524,86023,47543,137----
640/8 4,77346,13222,17618,90410,05610,08624,35223,640----
66A --963--03,500-----
9901 -47,568-266,905-25,25222,779331-20,49057,77738,51319,64123,821--
75/76B 28,68227,64828,18815,43315,3207,04910,26813,387----
75 28,68227,64828,18815,43315,3207,04910,26813,38714,98828,97026,06925,283
65/66B 135,9296,58023,51515,38210,0419,77610,8357,281----
65 135,9296,58023,51515,38210,0419,77610,8357,281----
9903 -154,487-244,214-21,54222,8297,181-23,21857,82944,619----
67/77 -6602,2289000-012,40916,993----
9904 -154,487-244,873-23,77021,9297,181-23,21845,41927,62626,06645,9158,34015,271
9905 -154,487-244,873-23,77021,9297,181-23,21845,41927,626----
Appropriation of the result
9906 -318,683-268,643-23,7705,893-16,036-23,21845,41927,626----
791/2 -104,447----------
691/2 --05,893-045,41927,626----
6920 ------02382,864---
6921 --05,893-045,41927,389----
694/7 -------0----
694 -------08,060---
Social balance sheet
9087 3.53.74.23.73.43.33.13.33.83.63.83.8
Hours worked1013 6,2146,4757,1585,7795,8315,7855,4415,889----
Document PDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDF

The accounts for 12 older financial years, from 1990 to 2001, were filed as documents without figures as data, scans for example.

Source: Annual accounts 2013 (PDF), filed on 05-06-2014.

Filings

each dot is a set of accounts, on the day it reached the National Bank
Financial year Type Filed Reference Document
31-12-2013 full format 05-06-2014 2014-16300085 PDF
31-12-2012 full format 24-07-2013 2013-35500413 PDF
31-12-2011 full format 15-06-2012 2012-18200167 PDF
31-12-2010 full format 30-05-2011 2011-13700022 PDF
31-12-2009 full format 13-07-2010 2010-30300168 PDF
31-12-2008 full format 12-06-2009 2009-23100376 PDF
31-12-2007 full format 25-06-2008 2008-28900239 PDF
31-12-2006 full format 18-06-2007 2007-24500291 PDF
31-12-2005 full format 24-07-2006 2006-53103376 PDF
31-12-2004 full format 06-07-2005 2005-44500088 PDF
31-12-2003 full format 27-07-2004 2004-53204640 PDF
31-12-2002 full format 30-09-2003 2003-72003845 PDF
31-12-2001 full format 07-10-2002 2002-64204318 PDF
31-12-2000 full format 26-09-2001 2001-58804741 PDF
31-12-1999 full format 03-10-2000 2000-61101642 PDF
31-12-1998 full format 03-08-1999 1999-39403907 PDF
31-12-1997 full format 15-06-1998 1998-17501009 PDF
31-12-1996 full format 23-06-1997 1997-19100839 PDF
31-12-1995 full format 04-07-1996 1996-31204131 PDF
31-12-1994 full format 11-08-1995 1995-45600028 PDF
31-12-1993 full format 08-12-1994 1994-49501046 PDF
31-12-1992 full format 30-06-1993 1993-20100001 PDF
31-03-1992 full format 10-07-1992 1992-21300521 PDF
31-03-1991 full format 15-10-1991 1991-28302983 PDF
31-03-1990 full format 28-09-1990 1990-24804748 PDF

Insights on PHARMA-LIBIN

The operating result for 2013 is a loss of €47,568, smaller than the loss of €266,905 in 2012.

Equity is negative. Debt of €470,855 exceeds the balance-sheet total of €220,372.

Large changes and their cause
  • 2013 Compared with 2012, equity fell by 161% and the balance sheet total by 68%. Last accounts before the absorption by MULTIPHARMA (effective 17-03-2014).